Asthma & Immunology annual meeting (AAAAI 2025). LP-003 demonstrated superior improvement compared to Omalizumab in mean change of UAS7 (urticaria activity score 7) from baseline and percentage ...
Co., Ltd. (referred to as "Longbio"), a leading biotech company dedicated to developing innovative biologic treatments for allergy, respiratory, dermatology, hematology, ophthalmology, and other ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback